OPN-6602

· Opna Bio LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OPN-6602, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

See pricing